C-reactive protein as a disease activity marker in rheumatoid arthritis
Keywords:
RA (rheumatoid arthritis), RF (rheumatoid factor), CRP (C - reactive protein), TLC (total leukocyte count), ESR (erythrocyte sedimentation rate)Abstract
Introduction: CRP is a valuable marker and regulator of systemic inflammation in RA that also appears to play a direct role in bone destruction and radiographic progression. CRP has also been implicated in the etiology of common comorbidities associated with RA. Decreasing CRP levels with RA treatment may contribute to reductions in disease activity, although beneficial effects of RA treatment seem to occur irrespective of CRP values. Aim: The purpose of this study was to examine whether levels of C-reactive protein (CRP), a sensitive marker of disease activity in rheumatoid arthritis (RA). Materials & methods: This study was carried out on 39 RF Positive patients from both sexes male and female from different age group at NIMS Super-Specialty Hospital, Sobha Nagar, Jaipur, Rajasthan. Inflammatory markers were performed in the laboratory. Results: In the current study, the majority of Rheumatoid Arthritis patients belong to the age group of 41 to 60 (58.97%) and male to female ration were 1:2. C - reactive protein found highly significant positive correlation. Out of total Rheumatoid Arthritis patients, 7.69% patients have normal C - reactive protein level and 92.30% have highly increased CRP level. T
Downloads
References
Shrivastava AK, Singh HV, Raizada A, Singh SK, Pandey A, Singh N, Yadav DS, Sharma H. Inflammatory markers in patients with rheumatoid arthritis. Allergologia et immunopathologia. 2015 Jan 1;43(1):81-7.
Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376:1094---108.
Deal CL, Meenan RF, Goldenberg DL, Anderson JJ, Sack B, Pastan RS, Cohen AS. The clinical features of elderly‐onset rheumatoid arthritis. A comparison with younger‐onset disease of similar duration. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 1985 Sep;28(9):987-94.
Kumar, S. (2022). A quest for sustainium (sustainability Premium): review of sustainable bonds. Academy of Accounting and Financial Studies Journal, Vol. 26, no.2, pp. 1-18
Allugunti, V.R. (2019). Diabetes Kaggle Dataset Adequacy Scrutiny using Factor Exploration and Correlation. International Journal of Recent Technology and Engineering, Volume-8, Issue-1S4, pp 1105-1110.
Viswanatha KKRC, Reddy A, Elango N M (2019). Diabetes Kaggle Dataset Adequacy Scrutiny using Factor Exploration and Correlation, International Journal of Recent Technology and Engineering (IJRTE) Vol. 8.
Fleming A, Crown JM, Corbett M. Prognostic value of early features in rheumatoid disease. Br Med J. 1976 May 22;1(6020):1243-5.
Yazici S, Yazici M, Erer B, Erer B, Calik Y, Ozhan H, Ataoglu S. The platelet indices in patients with rheumatoid arthritis: mean platelet volume reflects disease activity. Platelets. 2010 Jan 1;21(2):122-5.
Shin YS, Choi JH, Nahm DH, Park HS, Cho JH, Suh CH. Rheumatoid factor is a marker of disease severity in Korean rheumatoid arthritis. Yonsei Medical Journal. 2005 Aug 31;46(4):464-70.
Siemons L, Ten Klooster PM, Vonkeman HE, van Riel PL, Glas CA, van de Laar MA. How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis. BMC musculoskeletal disorders. 2014 Dec;15(1):1-7.
Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010, 69:631–637.
Ansar W, Ghosh S. C-reactive protein and the biology of disease. Immunol Res 2013;56:131–42.
Molenaar ET, Voskuyl AE, Familian A, van Mierlo GJ, Dijkmans BA, Hack CE. Complement activation in patients with rheumatoid arthritis mediated in part by C‐reactive protein. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2001 May;44(5):997-1002.
Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol 2018;9:754.
Newling M, et al. C-Reactive protein promotes inflammation through FcgR Induced glycolytic reprogramming of human macrophages. J Immunol 2019;203:225–35.
Lu J, et al. Structural recognition and functional activation of Fc gamma R by innate pentraxins. Nature 2008;456:989–92.
Rifai N, Ballantyne CM, Cushman M, Levy D, Myers GL. Point: high-sensitivity C-reactive protein and cardiac C-reactive protein assays: is there a need to differentiate?. Clinical chemistry. 2006 Jul 1;52(7):1254-6.
Genovese MC, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol 2015;67:1424–37.
Orr CK, Najm A, Young F, McGarry T, Biniecka M, Fearon U, Veale DJ. The utility and limitations of CRP, ESR and DAS28-CRP in appraising disease activity in rheumatoid arthritis. Frontiers in medicine. 2018 Aug 3;5:185.
Lee YJ, Lee JH, Shin YH, Kim JK, Lee HR, Lee DC: Gender difference and determinants of C-reactive protein level in Korean adults. Clin Chem Lab Med 2009, 47:863–869
Piéroni L, Bastard JP, Piton A, Khalil L, Hainque B, Jardel C: Interpretation of circulating C-reactive protein levels in adults: body mass index and gender are a must. Diabetes Metab 2003, 29:133–138.
Lakoski SG, Cushman M, Criqui M, Rundek T, Blumenthal RS, D'Agostino RB Jr, Herrington DM: Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J 2006, 152:593–598.
Shin YS, Choi JH, Nahm DH, Park HS, Cho JH, Suh CH. Rheumatoid factor is a marker of disease severity in Korean rheumatoid arthritis. Yonsei Medical Journal. 2005 Aug 31;46(4):464-70.
Milovanovic M, Nilsson E, Järemo P. Relationships between platelets and inflammatory markers in rheumatoid arthritis. Clinica chimica acta. 2004 May 1;343(1-2):237-40.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
